2.50
Hdl Handle:
http://hdl.handle.net/10541/76282
Title:
What's new in the management of cutaneous T-cell lymphoma?
Authors:
McFarlane, V; Friedmann, P S; Illidge, Timothy M ( 0000-0003-3191-7324 )
Abstract:
The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.
Affiliation:
Southampton Oncology Centre, Southampton University NHS Trust, Southampton S016 6YD, UK.
Citation:
What's new in the management of cutaneous T-cell lymphoma? 2005, 17 (3):174-84 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
May-2005
URI:
http://hdl.handle.net/10541/76282
PubMed ID:
15901002
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMcFarlane, V-
dc.contributor.authorFriedmann, P S-
dc.contributor.authorIllidge, Timothy M-
dc.date.accessioned2009-08-04T17:25:18Z-
dc.date.available2009-08-04T17:25:18Z-
dc.date.issued2005-05-
dc.identifier.citationWhat's new in the management of cutaneous T-cell lymphoma? 2005, 17 (3):174-84 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid15901002-
dc.identifier.urihttp://hdl.handle.net/10541/76282-
dc.description.abstractThe aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.en
dc.language.isoenen
dc.subject.meshHumans-
dc.subject.meshLymphoma, T-Cell, Cutaneous-
dc.subject.meshMycosis Fungoides-
dc.subject.meshPrognosis-
dc.titleWhat's new in the management of cutaneous T-cell lymphoma?en
dc.typeArticleen
dc.contributor.departmentSouthampton Oncology Centre, Southampton University NHS Trust, Southampton S016 6YD, UK.en
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.